A STUDY ON THE EFFECT OF LOW MOLECULAR WEIGHT ON POTASSIUM HOMEOSTASIS IN PATIENTS ADMINISTERED HEPARIN FOR THROMBOPROPHYLAXIS IN A TERTIARY CARE HOSPITAL

S. Shanmugapriya; K. Bhuvaneswari; K. Rashmi

doi:10.22159/ijpps.2017v9i6.18191

Authors

S. Shanmugapriya PSG Institute of Medical Sciences and Research
K. Bhuvaneswari PSG Institute of Medical Sciences
K. Rashmi PSG Institute of Medical Sciences

DOI:

https://doi.org/10.22159/ijpps.2017v9i6.18191

Keywords:

Serum potassium, Enoxaparin, Dalteparin, Hyperkalemia

Abstract

Objective: Low molecular weight heparin (LMWH) is an indirect thrombin inhibitor used clinically as an anticoagulant for thromboprophylaxis of patients at risk of deep vein thrombosis. The study was done to assess the magnitude of rise in serum potassium after administration of low molecular weight heparin comparing enoxaparin with dalteparin and to evaluate the frequency of clinically significant hyperkalemia in the population studied.

Methods: The study was done as a prospective non-randomized observational study in a population of 32 patients started on heparin for thromboprophylaxis for deep venous thrombosis, pulmonary thromboembolism or stroke.

Results: A statistically significant elevation in serum potassium was seen in patients treated with LMWH (p = 0.007). The magnitude of rise in potassium was significantly higher in enoxaparin (p = 0.008) than the dalteparin group (p = 0.447). A clinically relevant hyperkalemia of>5 mEq/l was seen in 25% of the population studied. Other important associations detected from the study were that the advancing age and increasing dose could be potential risk factors contributory to an accentuated rise in serum potassium which may culminate in clinically significant hyperkalemia.

Conclusion: The study has highlighted that the likelihood of rise in potassium levels during LMWH therapy necessitates monitoring of serum potassium.

Downloads

Download data is not yet available.

Author Biography

S. Shanmugapriya, PSG Institute of Medical Sciences and Research

Assistant Professor, Department of Pharmacology

References

Kuijvenhoven MA, Haak EA, Gombert-Handoko KB, Crul M. Evaluation of the concurrent use of potassium-influencing drugs as risk factors for the development of hyperkalemia. Int J Clin Pharm 2013;35:1099-104.

Bacon NC. Heparin-induced disturbance of potassium homeostasis. Q J Med 1997;90:725.

Thomas CM, Thomas J, Smeeton F, Leatherdale BA. Heparin-induced hyperkalemia. Diabetes Res Clin Pract 2008;80:e7-8.

Torres OH, Hernandez N, Francia E, Barcelo M, Mateo J, Ruiz D. Effect of prophylactic treatment with low-molecular-weight heparin bemiparin sodium on serum potassium levels: a prospective observational study. Drugs Aging 2010;27:399-406.

Olson NC, Cushman M, Lutsey PL, McClure LA, Judd S, Tracy RP, et al. Inflammation markers and incident venous thromboembolism: the REasons for geographic AND racial differences in the stroke (REGARDS) cohort. J Thromb Haemost 2014;12:1993-2001.

Aronow WS, Schoenfeld MR, Gutstein H. Frequency of thromboembolic stroke in persons greater than or equal to 60 y of age with extracranial carotid arterial disease and/or mitral annular calcium. Am J Cardiol 1992;70:123-4.

Gheno G, Savarino C, Vellar S, Cinetto L. Heparin-induced life-threatening hyperkalemia. Ann Ital Med Int 2002;17:51â€“3.

Gonzalez-Martin G, DÃaz-Molinas MS, MartÃnez AM, Ortiz M. Heparin-induced hyperkalemia: a prospective study. Int J Clin Pharmacol Ther Toxicol 1991;29:446â€“50.

Gheno G, Cinetto L, Savarino C, Vellar S, Carraro M, Randon M. Variations of serum potassium level and risk of hyperkalemia in inpatients receiving low-molecular-weight heparin. Eur J Clin Pharmacol 2003;59:373â€“7.

Bengalorkar GM, Sarala N, Venkatrathnamma PN, Kumar TN. Effect of heparin and low-molecular-weight heparin on serum potassium and sodium levels. J Pharmacol Pharmacother 2011;2:266â€“9.

Chiou-Tan FY, Garza H, Chan KT, Parsons KC, Donovan WH, Robertson CS, et al. Comparison of dalteparin and enoxaparin for deep venous thrombosis prophylaxis in patients with spinal cord injury. Am J Phys Med Rehabil 2003;82:678-85.

Krotenberg R, Adler U, Pomeranz B, Miller JD, Russell MW. Dalteparin vs. enoxaparin as prophylaxis for deep-vein thrombosis after total hip or knee arthroplasty: a retrospective analysis. Am J Phys Med Rehabil 2001;80:889-95.

Slavik RS, Chan E, Gorman SK, de Lemos J, Chittock D, Simons RK, et al. Dalteparin versus enoxaparin for venous thromboembolism prophylaxis in acute spinal cord injury and major orthopedic trauma patients: 'DETECT' trial. J Trauma 2007;62:1075-81.